A New Frontier of Precision Medicine: Using PET for Image-Guided Neurointerventions Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to share on Email (Opens in new window) ON DEMAND Experts discuss how PET/CT imaging can be used to enable image-guided neurointerventions and to study targeted delivery and clearance of therapeutic agents. WATCH WEBINAR Mice are by far the most frequently used animal for modeling disease and developing therapeutic strategies including neurointerventions. However, due to its anatomical and physiological barriers, the brain is a difficult target for delivery of therapeutic agents. Systemic administration is plagued with marginal brain accumulation and high risk of off-target side effects. In this webinar sponsored by Scintica Instrumentation, Dr. Piotr Walczak, Dr. Mirosław Janowski and Dr. Wojciech Lesniak address this challenge and discuss why advanced imaging is essential to perform image-guided neurointerventions. First, Dr. Janowski provides rationale as to how imaging can be used to better understand how therapeutic agents are delivered to the brain and subsequently cleared. Next, Dr. Walczak reviews methodological and technological advances for improving precision and reproducibility of brain targeting in mice based on MRI and two-photon microscopy. Finally, Dr. Lesniak presents recently-published results using ARGUS PET/CT to quantify intra-artrial delivery of antibodies, nanobodies and poly(amidoamine) dendrimers. Key Learning Objectives Include: - Why advanced imaging is essential to perform image-guided neurointerventions - Why we need to visualize not only penetration of therapeutic agents to the brain, but also their clearance - How image-guided procedures can be used to visualize and optimize delivery of therapeutic agents to the brain

1. Sponsored by:
Mirosław Janowski,
MD, PhD
Associate Professor,
Diagnostic Radiology and
Nuclear Medicine
University of Maryland School
of Medicine
Piotr Walczak,
MD, PhD
Professor, Diagnostic
Radiology and
Nuclear Medicine
University of Maryland
School of Medicine
Wojciech
Lesniak, PhD
Research Associate,
Department of
Radiology
John Hopkins School
of Medicine
A New Frontier of Precision
Medicine: Using PET for Image-
Guided Neurointerventions

2. Sponsored by:
A New Frontier of Precision
Medicine: Using PET for Image-
Guided Neurointerventions
Experts discuss how PET/CT imaging
can be used to enable image-guided
neurointerventions and to study
targeted delivery and clearance of
therapeutic agents.

3. InsideScientific is an online
educational environment
designed for life science
researchers. Our goal is to aid
in the sharing and distribution
of scientific information
regarding innovative
technologies, protocols,
research tools and laboratory
services

4. To access webinar content,
Q&A reports, FAQ documents,
and information on lab
workshops,
subscribe to our mail list

5. Miroslaw Janowski, MD, PhD
Piotr Walczak, MD, PhD
Wojciech Lesniak, PhD
A new frontier of precision medicine: using PET for
image-guided neurointerventions

6. •MJ and PW: co-founders and co-owners of IntraART, LLC
•MJ and PW: co-founders and co-owners of Ti-Com, LLC
Disclosures

7. Routes for delivery of therapeutic agent to the brain
Systemic delivery
Pros: Easy drug administration
Cons: 1) Whole-body toxicity
2) Need for high dose of drug
3) Limited penetration
of blood-brain barrier (BBB)
Intra-arterial delivery
Pros: 1) Focal BBB opening
2) Wide spatial distribution
3) Minimal invasiveness
4) Facile repeatability
Cons: 1) Need for advanced
imaging
Intracerebral delivery
Pros: Beyond BBB
Cons: 1) Skull and brain puncture
2) Limited spatial distribution
3) Need for long-lasting
infusions (days) and for
special devices
Intrathecal/CSF delivery
Pros: 1) Beyond BBB
2) Minimal invasiveness
3) Wide spatial distribution
4) Facile repeatibility
Cons: 1) Limited drug penetration
2) Limited possibility for focal
targeting

8. Historical perspective
Surgery, 1970
10 patients, 2 hemiplegia, 2 hemiparesis
Arch Neurol. 1964;11(6):618-625
French, J.D., et al., Effects of intracarotid administration of nitrogen mustard
on normal brain and brain tumors. J Neurosurg, 1952. 9(4): p. 378-89.

9. Zylber-Katz E. et al. Clin Pharmacol Ther
67:631–641, 2000
Variability!!!
Historical perspective
Cancer, 2000
• Between March 1994 and November 1997, 5 universities treated 221 adult
patients with intra-arterial chemotherapy with or without osmotic opening of
the BBB (2464 procedures).
• Of evaluable patients with PCNSL, 40 of 53 (75%) achieved complete
response (CR)
• All evaluable patients with PNET (n = 17), metastatic disease (n = 12), or germ
cell tumor (n = 4) achieved stable disease (SD) or better.
• Of 57 evaluable patients with glioblastoma multiforme, 45 (79%) achieved SD
or better.

10. Historical perspective

11. Super-selective intra-arterial drug delivery to the
brain – toward re-invention

12. FROM BED TO BENCH AND BACK AGAIN
our journey towards effective delivery of therapeutics to the brain
Intra-arterial route with transient opening of the blood brain barrier and image
guidance holds great promise

13. Gupta et al. Science Trans. Med. 4;155; 2012
Global dysmyelination
Children with PMD transplanted
with stem cells
T2w MRI @ 1 year
Uchida et al. Science Trans. Med. 4;155; 2012
Neonatal shiverer mice transplanted
with stem cells
WHY INTRA-ARTERIAL ROUTE?

14. WHY INTRA-ARTERIAL ROUTE?

15. WHY INTRA-ARTERIAL ROUTE?

16. Zylber-Katz E. et al. Clin Pharmacol Ther 67:631–641
THE CHALLENGE OF IA DELIVERY OF THERAPEUTIC
AGENTS TO THE BRAIN
Walczak et al. Stroke. 2008 May;39(5):1569-74.

17. • Cranial window implantation
• Catheterization of ICA
• Visualization of trans-catheter
perfusion and osmotic opening
cortical BBB guided by MRI
• Intravital multiphoton microscopy
of IA IgG extravasation
• PET imaging
MULTIMODALITY IMAGING PLATFORM FOR GUIDING
IA DELIVERY IN MICE

18. GE-EPI
fast (2s/volume), highly sensitive to
MRI contrast
FastSlow
Walczak P, et al. J Cereb Blood Flow Metab 2017.
VISUALIZATION TRANS-CATHETER PERFUSION WITH
INTERVENTIONAL MRI

19. EXCESSIVE INFUSED SPEED INTO ICA (0.2ml/min)
CAUSED BRAIN DAMAGE

20. Pterygopalatine Artery NOT Ligated
VISUALIZATON OF IA CELL INFUSION UNDER REAL
TIME MRI

21. Pterygopalatine Artery Ligated
VISUALIZATON OF IA CELL INFUSION UNDER REAL
TIME MRI

22. Small cells (mGRPs) Large cells (rMSCs)
VISUALIZATON OF IA CELL INFUSION UNDER REAL TIME
MRI

23. 3-dayoldouabainstroke
Beforetransplantation
Aftertransplantation
Red– transplantedcells
Green– vessels(vWF)
DAPI
Intraarterialinjection ofGRPs
Jablonska et al. J Cereb Blood Flow
Metab 2018 May;38(5):835-846
CAN CELLS EXTRAVASATE?

24. 30 min
after TX
120 min
after TX
50 min
after TX
90 min
after TX
VISUALIZATION OF DIAPEDESIS BY TWO PHOTON
MICROSCOPY
Jablonska et al. J Cereb Blood Flow
Metab 2018 May;38(5):835-846

25. • Impermeable to water soluble drugs >180 Da
• Most therapeutic agents are larger
Most capillaries Brain capillaries
Hyperosmotic
agent (Mannitol)
BLOOD BRAIN BARRIER AND ITS CONTROLLED OPENING

26. Disruption of BBB
with Intraarterial
Mannitol (25%)
Transcatheter DSC MRI
GE-EPI
T1 MRI +Gd for
assessment of BBB
integrity
Catheter placed in ICA
Animal placed in 11.7T
MRI scanner
MRI-GUIDED BBBD IN MICE
Mouse

27. Mri-guided intraarterial catheter-based method for
predicting territory of local blood brain barrier opening
US Patent: WO2015179258A3
MRI-GUIDED OBBBO IN MICE
Chu et al. Front Neurol. 2018; 9: 921

28. SAFETY OF OBBBO IN MICE
Chu et al. Front Neurol. 2018; 9: 921

29. VARIABILITY OF CORTICAL PERFUSION DURING
CONTRAST AGENT INFUSION VIA ICA (O.5ml/min)
Chu et al. J Control Release
2020 Jan 10;317:312-321

30. Dynamic EPI
TEMPORARY CLOSURE OF THE CONTRALATERAL CCA
OPENS CORTICAL PERFUSION
Chu et al. J Control Release
2020 Jan 10;317:312-321

31. cCCA
closure
Mannitol
Gd
Dynamic imaging of IgG extravasation under 2 photon microscopy
Rhodamine
(0.53 kDa)
FITC-antibody
(1.53 kDa)
Chu et al. J Control Release
2020 Jan 10;317:312-321

32. Chu et al. J Control Release
2020 Jan 10;317:312-321
DYNAMIC IMAGING OF IgG EXTRAVASATION UNDER
TWO PHOTON MICROSCOPY

33. Chu et al. J Control Release
2020 Jan 10;317:312-321
HISTOLOGICAL ASSESSMENT OF BV EXTRAVASATION

34. MRI is excellent for visualization trans-catheter perfusion, monitoring BBB status but
sensitivity is rather low and insufficient for detection of injected drugs
Intravital 2PM offers subcellular resolution and high sensitivity, but very small
imaging area and is hardly quantitative
PET is highly sensitive enables quantitative, whole body imaging of injected drugs
BOTTOM LINE

35. Technique Resolution Sensitivity Quantification
MRI 10 - 100 µm µ - m Mol Non-
quantitative
PET 1 - 2 mm p - n Mol Quantitative
Comparison of MRI and PET
89Zr or 64Cu
p - nMol
PET contrast agent
SPIO
mMol
MRI contrast agent

36. Positron Emission Tomography (PET)
https://en.wikipedia.org/wiki/Positron_emission_tomography
“Organic-atom-like”: 18F (t1/2=109.7 min), 11C
(t1/2=20.33 min), 13N (t1/2=9.97 min), 15O (t1/2=2.03
min), 124I (t1/2=4.18 d)
Radiometals: 68Ga (t1/2=68 min), 64Cu (t1/2=12.7
h), 89Zr (t1/2=78.4 h)

37. 1 2 .5 2 5 .0
-1 0
0
1 0
2 0
3 0
4 0
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
tim e [m in ]
mV
Abs.at280nm
0 5 1 0 1 5 2 0 2 5
0
5 .0 1 0 5
1 .0 1 0 6
1 .5 1 0 6
0
1 0
2 0
3 0
4 0
5 0
NH2 +
O
N
HN
O
O N
NH
OH HO
O
O
N
HOH
N
S
H
N
SCN
NH
O
N
H
N
O
O N
NH
OH HO
O
O
N
HOH
N
S
H
N
N
H
S
NH
O
N
H
N
O
O N
NH
OH
HO
O
O
N
HOH
N
O
H
N
N
H
S
+ 89Zr4+
NH
O
N
HN
O
O N
NH
O
O
O
O
N
OH
N
S
H
N
N
H
S
89
Zr4+
m /z
1 4 0 0 0 0 1 5 0 0 0 0 1 6 0 0 0 0
B V
B V -D F O
150215
152410
Radiolabeling of Bevacizumab with Zirconium-89
Bevacizumab (BV) DFO-Bz-NCS
HEPES, pH=7.2
1 h, RT
[89Zr]BV
BV-DFO
pH=9, 1 h, 37 oC
1:5 molar ratio
Abs.at450nm
2 5  g /m L 5 0  g /m L 1 0 0  g /m L
0 .2
0 .4
0 .6
0 .8
1 .0
B V
B V -D F O
BV
[89Zr]BV
Lesniak WG, Chu C, et al. J. Nucl. Med. 2019, 60(5):617-622
MALDI-TOF Binding to VEGF SEC

38. Experimental Setup
I - intra-arterial infusion with intact blood brain barrier (IA/IBBB)
II - osmotic blood brain barrier opening and intra-arterial infusion (OBBBO/IA)
III - osmotic blood brain barrier opening and intravenous infusion (OBBBO/IV)
Evaluated macromolecules: Antibodies, Nanobodies and
Poly(amidoamine) dendrimers

39. T im e [m in ]
%ID/cc
0 5 1 0 1 5 2 0 2 5 3 0
0
5
1 0
1 5
2 0
2 5
3 0
3 5
Time [min]%ID/cc
0 5 10 15 20 25 30
0
10
20
30
40
ipsilateral hemisphere heart
OBBBO and IA infusionIA infusion with IBBB OBBBO and IV infusion
0
75
*
*
Kinetics of [89Zr]BV Uptake in Ipsilateral Hemisphere
Lesniak WG, Chu C, et al. J. Nucl. Med. 2019, 60(5):617-622

40. 0
75
Distribution of [89Zr]BV in Brain
R
S
T
R
L
S
T
R
C
T
X
R
H
IP
L
H
IP
T
H
A
C
B
B
F
S
H
Y
P
R
A
M
Y
L
A
M
Y
B
S
C
G
S
C
O
L
F
R
M
ID
L
M
ID
L
IC
R
IC
0
5
1 0
1 5
2 0
%ID/cc
G ro u p I
G ro u p II
G ro u p III
STR striatum
CTX cerebral cortex
HIP hippocampus
THA thalamus
CB cerebellum
BFS basal forebrain septum
HYP hippocampus
AMY amygdala
BS brain stem
CG central gray
SC superior colliculi
OLF olfactory bulb
MID midbrain
IC inferior colliculi
*
*
*
*
*
*
*
**
*
*
OBBBO and IA infusionIA infusion with intact BBB IV infusion and OBBBO
Lesniak WG, Chu C, et al. J. Nucl. Med. 2019, 60(5):617-622

41. 40
0
40
0
40
0
1 h pi 1 h pi 24 h pi
1 h pi 24 h pi
%ID/cc
1
h
2
4
h
1
h
2
4
h
1
h
2
4
h
0
5
1 0
1 5
2 0
2 5
IA /B B B I
B B B O /IA
IV /B B B O
OBBBO/IAIA/BBBI
IV/OBBBO
Whole Body PET/CT Imaging of [89Zr]BV
24 h pi
ipsilateral hemisphere
Lesniak WG, Chu C, et al. J. Nucl. Med. 2019, 60(5):617-622. doi: 10.2967/jnumed.118.218792

42. Ex Vivo Biodistribution of [89Zr]BV
*
*
OBBBO/IA
IA/IBBB
OBBBO/IV
Lesniak WG, Chu C, et al. J. Nucl. Med. 2019, 60(5):617-622. doi: 10.2967/jnumed.118.218792

43. Perspectives

44. Radiolabeling of Anti-gelsolin Nanobody with 89Zr
NB
DFO-Bz-NCS
HEPES, pH=7.2
1 h, RT
89ZrNB
pH=9, 1 h, 37 oC
1:5 molar ratio
NB-DFO
NB-DFO
Lesniak WG, Chu C, et al. Eur J Nucl Med Mol Imaging. 2019, doi: 10.1007/s00259-019-04347-y.

45. T im e [m in ]
%ID/cc
0 5 1 0 1 5 2 0 2 5 3 0
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
O B B B O /IA
IA /B B B I
IV /O B B B O
OBBBO/IA IA/BBBI OBBBO/IV
0
100
%ID/cc
Kinetics of [89Zr]NB Uptake in Ipsilateral Hemisphere
Lesniak WG, Chu C, et al. Eur J Nucl Med Mol Imaging. 2019, doi: 10.1007/s00259-019-04347-y.

46. OBBBO/IA 1 h pi
OBBBO/IA 24 h pi
IA/BBBI 1 h pi
IA/BBBI 24 h pi
OBBBO/IV 1 h pi
OBBBO/IV 24 h
pi
Whole Body PET/CT Imaging of [89Zr]NB11
100
0
100
0
Lesniak WG, Chu C, et al. Eur J Nucl Med Mol Imaging. 2019, doi: 10.1007/s00259-019-04347-y.

47. Synthesis of Poly(amidoamine) Dendrimers
NH
Generation 2
Generation 1
N N
N
N
N
N
NH2
NH2
H2N
NH2
NH2
H2N
H2
N
2
N N
N
N
N
N
N
N
N
N
NH2
NH2
NH2
H2N
N
N
N
N
H2N
H2N
H2N
H2N
H2N NH2
NH2
H2N
NH2
H2N
NH2
NH2
(2)
NH2
H2N
(1)
O
OMe
(1)
O
OMe
(2)
NH2
H2N
Generation 3, etc.
Up to generation 12
Core
NN
O
N
O
N
N
H2N NH2
Generation 0
N N
H2N
H2N
NH2
NH2
N N
NH
N
O
H
H
HN
H2
O
H
H2 H
(1)
O
OMe
(2) NH2H2N
2
2

48. PAMAM Dendrimer Based Nanoparticles
therapeutics
contrast agents (X-ray, MRI)
targeting
agents
NHCCH3
O
CH2CHCH2OH
OH
CH2CHCH2OH
OH
N
NHCCH2CH2C
O
O
O-
NHC(OCH2CH2)nOH
O
Applications:
• Selective and controlled drug deliver
• Gene transfection
• Contrast agents
• Immunoassay and molecular diagnostic
platforms
• Nanocomposites
surface modification

49. HN
(NH2)64
1) DFO-Bz-NCS, 2) Glycidol
O
N
NH
O
ON
HN
HOOH
O
O
N
OH H
N
S
H
N
N
H
S
OH
OH
NH
12
89
Zr4+
O
N
NH
O
ON
HN
O
O
O
O
N
O H
N
S
H
N
N
H
S
89
Zr4+
NH OH
OH
NH
12
3 3
OH
OH
N
49
OH
OH
OH
OH
N
49
OH
OH
Modifications of Dendrimer and Radiolabeling
with Zirconium-89
89ZrG4(DFO)3(Bdiol)110G4(DFO)3(Bdiol)110G4(NH2)64
Lesniak WG, Chu C, et al. Eur J Nucl Med Mol Imaging. 2019, doi: 10.1007/s00259-019-04347-y.

50. OBBBO/IA
IA/BBBI
OBBBO/IV
PET Imaging and Kinetics of 89ZrG4(DFO)3(Bdiol)110
Uptake in Ipsilateral Hemisphere
0
30
0
40
0
6
1 h piFrames 5 to 10 min
%ID/cc
%ID/cc
%ID/cc
T im e [m in ]
%ID/cc
0 5 1 0 1 5 2 0 2 5 3 0
0
1
2
3
4
5
6
O B B B O /IA
IA /B B B I
IV /O B B B O
N
S
*
Lesniak WG, Chu C, et al. Eur J Nucl Med Mol Imaging. 2019,
doi: 10.1007/s00259-019-04347-y.

51. OBBBO / IA 24 h pi
IA/BBBI 1 h pi
IA / BBBI 24 h pi
IV/BBBI 1 h pi
IV / BBBI 24 h pi
100
0
100
0
OBBBO/IA 1 h pi
Whole Body PET-CT Imaging of 89ZrG4(DFO)3(Bdiol)110
Lesniak WG, Chu C, et al. Eur J Nucl Med Mol Imaging. 2019, doi: 10.1007/s00259-019-04347-y.

52. Ex Vivo Biodistribution of 89ZrG4(DFO)3(Bdiol)110
at 24 h After Infusion
B
lood
Ipsilateralhem
isphere
C
ontralateralhem
isphere
H
eart
Lung
Liver
Thym
us
S
tom
ach
P
ancreas
S
pleen
K
idney
Fat
M
uscle
B
ladder
0
5
10
15
20
25
30
35
40
%ID/g
O B B B O /IA
IV /O B B B O
IA /B B B I
Ipsilateral hem
isphere
C
ontralateral hem
isphere
0 .0 0
0 .0 5
0 .1 0
0 .1 5
%ID/g
Lesniak WG, Chu C, et al. Eur J Nucl Med Mol Imaging. 2019, doi: 10.1007/s00259-019-04347-y.

53. Conclusions
 IA delivery of antibodies or nanobodies might be an attractive therapeutic
platform for treatment of CNS disorders
 Appropriate surface modification of PAMAM dendrimers with targeting agents
may facilitate specific uptake for selective drug delivery

54. Evaluation of PSMA-Targeted PAMAM Dendrimer
Lesniak WG et al., Mol Pharm. 2019, doi: 10.1021/acs.molpharmaceut.9b00181
Rhodamine
64Cu
PAMAM
G4
Lys-Glu-urea
PSMA+
PSMA-
Optical imaging
25
0
PET-CT
PSMA+ PSMA-

55. Optical and Photoacoustic Imaging of PSMA-targeted Dendrimer
5 hrs ai
PIP flu
dorsal ventraldorsal dorsal ventraldorsal
24 hrs ai
ventraldorsal
48 hrs ai
ventraldorsal
72 hrs ai
flu
1 2
3
4 5 6 7
8 9 10
11 12
13
14
15
PIP
PIPflu
1 - heart, 2 - lung, 3 - liver, 4 - pancreas, 5 - spleen, 6 - fat, 7 - kidneys,
8 -muscle,9 - small intestines, 10 - salivary glands, 11 - bladder, 12 - bone,
13 - lacrimal gland,14 - PSMA+ PC3 PIP, 15 - PSMA- PC3 flu

56. First-in-man real-time MRI-guided endovascular neurointervention
Zawadzki et al., JNISfaster infusion slower infusion

57. Publication: JNIS/BMJ Case REPORTS

58. • Intra-arterial route of delivery of therapeutic agents to the brain is becoming increasingly attractive.
• Advanced imaging is essential to precisely guide the procedure
• Advances
• Progress in imaging of intra-arterial interventions (MRI + PET)
• Drug design especially related to safety aspects (antibodies + macromolecules)
• Catheter design – reaching distal vessels allows for precise interventions
• Advantages
• Decreasing exposure of therapeutic agents to the peripheral organs
• No skull opening
• Easily repeatable
• Future directions:
• Design of MRI-visible microcatheters for endovascular neurointerventions
• Engineering of cells and molecules to better benefit from intra-arterial delivery
• Application of PET-MRI in interventional suites to benefit from advantages of high spatial resolution of MRI and high
sensitivity of PET during the same procedure to allow for unprecedented precision
Summary

59. Acknowledgments
GROUP:
Anna Jablonska
Yajie Liang
Chengyan Chu
Xiaoyan Lan
Yue Gao
Jipeng Zhang
Dariush Aligholizadeh
COLLABORATORS:
Graeme Woodworth
Rao Gullapalli
Linda Chang
Thomas Ernst
Ze Wang
Collaborators:
Monica Pearl
Martin Pomper
Guanshu Liu
Collaborators:
Izabela Malysz-Cymborska
Dominika Golubczyk
Lukasz Kalkowski
Wojciech Maksymowicz
Collaborators:
Barbara Lukomska
Luiza Stanaszek
Anna Andrzejewska
Katarzyna Drela
Sylwia Dabrowska
Piotr Rogujski
Collaborators:
Michal Zawadzki
Malgorzata Dorobek
Blazej Nowak
Collaborators:
Miguel Oliveira
Eduarda Oliveira
Johannes Boltze
Tim Magnus
Matthias Gelderblom
Peter Ludewig
Jan Gettemans
Olivier Zwaenepoel
Pedro Ramos Cabrer
Jesus Ruiz-Cabello
Supported by MSCRFII-0193, MSCRFII-0052, MSCRFE-0178, RO1 NS076573, 2RO1 NS045062, EUREKA
RO1DA026299, R21NS106436, R01NS091100, R01NS091110, P41 EB024495 EXPLORE ME

60. SIGN 2019

61. SIGN 2021

62. The University of Nottingham, UK
David Walker, Chair
Ruman Rahman, Deputy Chair
Richard Grundy
Emma Campbell, Project Manager
University of Strathclyde, UK
Marie Boyd
Alexander Mullen
Newcastle University, UK
Gareth Veal
Bristol Royal Hospital for Children, UK
Stephen Lowis
UCL Institute of Child Health
Darren Hargrave
Johns Hopkins University, US
Henry Brem
Monica Pearl
Jordan Green
Miroslaw Janowski
Kenneth Cohen
Piotr Walczak
National Cancer Institute
Katherine Warren
VU University Medical Centre, Amsterdam
Dannis van Vuurden
Fast Track Pharma Ltd
Steven Powell
Consortium – invitation to register

63. Sponsored by:
Mirosław Janowski,
MD, PhD
Associate Professor,
Diagnostic Radiology and
Nuclear Medicine
University of Maryland School
of Medicine
Piotr Walczak,
MD, PhD
Professor, Diagnostic
Radiology and
Nuclear Medicine
University of Maryland
School of Medicine
Wojciech
Lesniak, PhD
Research Associate,
Department of
Radiology
John Hopkins School
of Medicine
To learn more about Scintica’s solutions for
preclinical PET-CT imaging, please visit:
https://www.scintica.com/products/superargus-
sedecal-pet-ct-preclinical-systems/
Thank you!